Institut Curie kondigt oprichting Honing Biosciences aan
PARIJS—(BUSINESS WIRE)– Institut Curie, een belangrijke speler in de strijd tegen kanker, kondigt de lancering aan van het biotechnologiebedrijf Honing Biosciences. Het bedrijf bezit een exclusief technologieplatform om oplossingen te ontwikkelen voor het optimaliseren van de effectiviteit en veiligheid van celtherapie bij kanker en chronische ziekten. In eerste instantie zal Honing Biosciences zich richten op het strategische gebied van kankerimmunotherapie, in het bijzonder CAR-T cellen. Met de intrede in het kapitaal van de start-up markeert Institut Curie haar vertrouwen in de ontwikkeling van Honing Biosciences en concretiseert het haar nieuwe technologietransferbeleid dat in 2017 werd geïmplementeerd.
Dit persbericht bevat multimedia. Bekijk hier het volledige persbericht: https://www.businesswire.com/news/home/20180914005368/en/
Institut Curie Announces Creation of Honing Biosciences
PARIS–(BUSINESS WIRE)– Institut Curie, a key player in the fight against cancer, announces the launch of the biotechnology company Honing Biosciences. The company owns an exclusive technology platform to develop solutions to optimize the efficacy and safety of cell therapy in cancer and chronic diseases. Initially, Honing Biosciences will focus on the strategic area of cancer immunotherapy, particularly CAR-T cells. By entering the capital of the start-up, Institut Curie marks its confidence in the development of Honing Biosciences and materializes its novel technology transfer policy implemented in 2017.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180914005368/en/
“CellTune ™ molecular technology allows the development of a new class of cell therapies by controlling the dynamic distribution of proteins in “cell-medicaments”. We can regulate the expression of proteins on the cell surface or the secretion of enzymes, cytokines and antibodies, to adapt the delivery of therapeutic proteins to patient clinical evolutions ” says Franck Perez, co-founder of Honing Biosciences and CNRS Research Director at Institut Curie.
CAR-T cells show therapeutic efficacy in blood cancers, but can also be toxic. In solid tumors, there is still no conclusive result. Honing Biosciences’ technology allows considering the development of effective approaches, safe and affordable” says Sebastian Amigorena, scientific advisor of Honing Biosciences and Director of the Cancer Immunotherapy Center of Institut Curie.
“Honing Biosciences proprietary protein transport control technology shall attract partners in the cell therapy sector, a highly dynamic market that has been growing continuously for several years. This is an emblematic example of fundamental research that will ultimately benefit to patients treated at the Institute through the development of a start-up and reveals the institute entrepreneurial dynamics ” says Amaury Martin, head of Institut Curie Technology Transfer and Industrial Partnerships Department and Director of the Carnot Institute Curie Cancer.
“Cell therapy is one of the major advances of recent years in research and especially in the fight against cancer. This is a rapidly changing market and we are seeing great interest in our proprietary technology from industry and investors. We will quickly identify the future partners of Honing Biosciences” concludes Abdelkader Bousabaa, co-founder and CEO of Honing Biosciences.
More information: http://www.honing-biosciences.com https://techtransfer.institut-curie.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180914005368/en/
Contacts
Institut Curie
Press:
Hélène Bléher, +331 41 34 18 65
hbleher@hopscotch.fr